Q-omics provides the consensus-scored MIR625 profile across patient tissues and cancer cell-line models. MIR625 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR625 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, MIR625 RNA expression shows 7,816 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight HNSC, STAD, and UCEC as cancer lineages where MIR625 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR625 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR625 survival associations across molecular data types. MIR625 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR625 RNA expression–survival associations across cancer types. High MIR625 expression shows unfavorable associations in ESCA, KIRC, DLBC and LGG, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .016). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR625 RNA expression.
This table summarizes MIR625 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR625. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR625 shows higher tumor expression in STAD. The STAD box plot shows higher MIR625 RNA expression in tumor versus normal tissue (log2 FC = +0.186, t-test p = .017).
This table shows molecular features associated with MIR625 in patient tissues and cancer cell lines. In patient samples, MIR625 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
